China pharma's candesartan hypertension product passes bioequivalence tests and the company plans to apply for nmpa approval

Haikou, china , aug. 5, 2021 /prnewswire/ -- china pharma holdings, inc. (nyse american: cphi) ("china pharma," the "company" or "we"), a specialty pharmaceutical company, today announced that its candesartan hypertension product passed key bioequivalence tests. the company plans to use the results of the key benchmark tests of consistency evaluation to apply for the national medical products administration's (nmpa) approval.
CPHI Ratings Summary
CPHI Quant Ranking